Atomoxetine oral solution - TAHO Pharmaceuticals
Alternative Names: TAH-9922Latest Information Update: 28 Jul 2025
At a glance
- Originator TAHO Pharmaceuticals
- Class Behavioural disorder therapies; Propylamines
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder(In adolescents, In children) in China (PO, Liquid)
- 26 Oct 2023 Atomoxetine oral solution licensed to Kye Pharmaceuticals in Canada
- 26 Oct 2023 Kye Pharmaceuticals announces intention to commercialize Atomoxetine oral solution in Canada